Date | Product | Disease | Phase | Company | Therapeutic area |
---|---|---|---|---|---|
2014-08-25 | Pradaxa® (dabigatran etexilate mesylate) | patients with non-valvular atrial fibrillation (NVAF) patients who have experienced deep venous thrombosis (DVT) and pulmonary embolism (PE) |
Boehringer Ingelheim (Germany) | Cardiovascular diseases | |
2014-08-25 | Xarelto® (rivaroxaban) | patients with atrial fibrillation undergoing cardioversion | 3b | Bayer Healthcare (Germany) | Cardiovascular diseases |
2014-08-25 | eculizumab | prevention of delayed graft function after kidney transplantation | 2-3 | Alexion Pharmaceuticals (USA - CT) | Transplantation |
2014-08-22 | HTI-1968 | human papillomavirus infection |
preclinical | Hera Therapeutics (USA - CA) | Infectious diseases |
2014-08-21 | BAX 855 | hemophilia A |
3 | Baxter International (USA - IL) | Hematological diseases - Genetic diseases - Rare diseases |
2014-08-20 | KVD001 | diabetic macular edema |
1 | KalVista Pharmaceuticals (UK) | Metabolic diseases - Ophtalmological diseases |
2014-08-19 | ARGX-113 | autoimmune diseases |
preclinical | Argen-X (The Netherlands-Belgium) | Autoimmune diseases |
2014-08-19 | Revlimid® (lenalidomide) | untreated diffuse large b-cell lymphoma (DLBCL) |
2 | Celgene (USA - NJ) | Cancer - Oncology |
2014-08-19 | allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) | Alzheimer’s disease |
preclinical | Stemedica International (Switzerland) | Neurodegenerative diseases |
2014-08-18 | erlotinib, crizotinib | early-stage lung cancer | NCI (USA) Response Genetics (USA - CA) Pfizer (USA - NJ) Astellas Pharma (Japan) | Cancer - Oncology | |
2014-08-18 | TurboHawk™ and SilverHawk™ directional atherectomy systems | critical limb ischemia (CLI) peripheral arterial disease |
Covidien (Ireland) | Cardiovascular diseases | |
2014-08-18 | AMG 416 | secondary hyperparathyroidism in patients with chronic kidney disease (CKD), receiving hemodialysis |
3 | Amgen (USA - CA) | Hormonal diseases - Endocrine diseases - Renal diseases - Kidney diseases |
2014-08-14 | CHS-1420 (biosimilar version of Humira® (adalimumab)) | Coherus BioSciences (USA - CA) | Autoimmune diseases | ||
2014-08-14 | KB004 (Humaneered® anti-EphA3 monoclonal antibody) | preclinical | KaloBios Pharmaceuticals (USA -CA) | Cancer - Oncology | |
2014-08-13 | Kyprolis® (carfilzomib) | relapsed and advanced refractory multiple myeloma |
3 | Amgen (USA - CA) | Cancer - Oncology |
2014-08-12 | JVS-100 | ischemic heart failure |
1-2 | Juventas Therapeutics (USA - OH) | Cardiovascular diseases |
2014-08-12 | NormoCort® (COR-003 or 2S, 4R ketoconazole) | Cushing's syndrome |
3 | Cortendo (Sweden) | Rare diseases |
2014-08-12 | DNA ImmunoBody® vaccine SCIB1 | preclinical | Scancell Holdings (UK) | Cancer - Oncology | |
2014-08-12 | SGN-CD70A | renal cell carcinoma
|
1 | Seattle Genetics (USA - WA) | Cancer - Oncology |
2014-08-12 | EPZ-6438 (E7438) | advanced solid tumors B-cell lymphomas |
preclinical | Epizyme (USA - MA) Eisai (Japan) | Cancer - Oncology |